Medicinova Inc (MNOV) 10-Q Quarterly Report November 2021

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2021	Nov. 09, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Trading Symbol	MNOV
Entity Registrant Name	MEDICINOVA, INC.
Entity Central Index Key	0001226616
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		49,043,246
Entity Shell Company	false
Entity File Number	001-33185
Entity Tax Identification Number	33-0927979
Entity Address, Address Line One	4275 Executive Square
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	La Jolla
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92037
City Area Code	858
Local Phone Number	373-1500
Entity Current Reporting Status	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1226616/000156459021056378/mnov-10q_20210930.htm

View differences made from one quarter to another to evaluate Medicinova Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Medicinova Inc.

Continue

Assess how Medicinova Inc's management team is paid from their Annual Proxy

Medicinova Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

Other

Filter Subcategory:

All

Expense

Geography

Product

Other

Inside Medicinova Inc's 10-Q Quarterly Report:

Financial - Expense Highlight
To the extent that costs, including personnel costs, are not tracked to a specific product development program, such costs are included in the "Other R&D expense" category (in thousands): Our general and administrative costs primarily consist of salaries, stock-based compensation, benefits and consulting and professional fees related to our administrative, finance, human resources, business development, legal, information systems support functions, facilities and insurance costs.

Financial - Expense Highlight
Research, development and patents costs are expensed as incurred and we expect to increase such costs through the remainder of 2021 as our development programs progress.
Other - Other Highlight
The $3.2 million change is primarily related to the decreased net loss and changes in operating assets and liabilities for those periods.
Financial - Expense Highlight
The increase of $1.1 million was primarily due to higher clinical trial expenses from the ongoing clinical trial of MN-166 (ibudilast) in ALS.
Financial - Expense Highlight
16 Our research, development and patents expenses consist primarily of license fees related to our product candidates, salaries and related employee benefits, costs associated with the preclinical and clinical development of our product development programs, costs associated with non-clinical activities, such as regulatory expenses, and pre-commercialization manufacturing development activities.
Revenue - Geography
In October 2011, we entered...Read more
Revenue - Product
No revenue was recognized in...Read more
Financial - Expense
Internal research and development expenses...Read more
Other - Other
As a result, we are...Read more
Other - Other
We do not have relationships...Read more
Financial - Expense
Our general and administrative expenses...Read more
Other - Other
For example, we contributed financially...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Medicinova Inc provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: MNOV
CIK: 1226616
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-21-056378
Submitted to the SEC: Fri Nov 12 2021 6:03:28 AM EST
Accepted by the SEC: Fri Nov 12 2021
Period: Thursday, September 30, 2021
Industry: Pharmaceutical Preparations